SG11202004906QA - Radiolabeling of polypeptides - Google Patents

Radiolabeling of polypeptides

Info

Publication number
SG11202004906QA
SG11202004906QA SG11202004906QA SG11202004906QA SG11202004906QA SG 11202004906Q A SG11202004906Q A SG 11202004906QA SG 11202004906Q A SG11202004906Q A SG 11202004906QA SG 11202004906Q A SG11202004906Q A SG 11202004906QA SG 11202004906Q A SG11202004906Q A SG 11202004906QA
Authority
SG
Singapore
Prior art keywords
radiolabeling
polypeptides
Prior art date
Application number
SG11202004906QA
Inventor
Vadim Dudkin
Shalom Goldberg
Joseph Erhardt
Rhys Salter
Theresa Mcdevitt
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of SG11202004906QA publication Critical patent/SG11202004906QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008Peptides; Proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11202004906QA 2017-12-18 2018-12-17 Radiolabeling of polypeptides SG11202004906QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762599830P 2017-12-18 2017-12-18
PCT/US2018/065913 WO2019125982A1 (en) 2017-12-18 2018-12-17 Radiolabeling of polypeptides

Publications (1)

Publication Number Publication Date
SG11202004906QA true SG11202004906QA (en) 2020-07-29

Family

ID=65003549

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004906QA SG11202004906QA (en) 2017-12-18 2018-12-17 Radiolabeling of polypeptides

Country Status (15)

Country Link
US (1) US20210017099A1 (en)
EP (1) EP3727474A1 (en)
JP (2) JP2021506842A (en)
KR (1) KR20200100094A (en)
CN (1) CN111491670A (en)
AU (1) AU2018388467A1 (en)
BR (1) BR112020012099A2 (en)
CA (1) CA3085465A1 (en)
EA (1) EA202091420A1 (en)
IL (1) IL275242A (en)
MX (1) MX2020006395A (en)
PH (1) PH12020550690A1 (en)
SG (1) SG11202004906QA (en)
WO (1) WO2019125982A1 (en)
ZA (1) ZA202004424B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092839A1 (en) 2018-05-24 2021-02-12 Янссен Байотек, Инк. PSMA LINKING AGENTS AND THEIR APPLICATIONS
WO2022080481A1 (en) * 2020-10-16 2022-04-21 日本メジフィジックス株式会社 Radioactive complexes of anti-her2 antibody, and radiopharmaceutical
CN113747944A (en) * 2019-04-19 2021-12-03 詹森生物科技公司 Methods of treating prostate cancer with anti-PSMA/CD 3 antibodies
PE20220935A1 (en) 2019-05-10 2022-05-31 Janssen Biotech Inc MACROCYCLIC CHELATORS AND METHODS OF USE OF THESE
AU2020319963B2 (en) * 2019-07-30 2023-04-27 Jfe Engineering Corporation Method for synthesizing zirconium complex
JPWO2021075546A1 (en) 2019-10-18 2021-04-22
EP4092016A4 (en) * 2020-01-16 2024-01-17 JFE Engineering Corporation Method for synthesizing zirconium complex
KR20220154728A (en) 2020-03-13 2022-11-22 얀센 바이오테크 인코포레이티드 Materials and methods for binding SIGLEC-3/CD33
JP2023527149A (en) * 2020-05-19 2023-06-27 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Methods, systems and kits for polypeptide processing and analysis
KR20230011417A (en) 2020-05-20 2023-01-20 얀센 바이오테크 인코포레이티드 Methods for Site-Specific Conjugation of Proteins Comprising a Glycosylated Fc Domain
WO2022203082A1 (en) * 2021-03-26 2022-09-29 日本メジフィジックス株式会社 Compound, method for producing and method for storing compound, method for producing targeting agent, and composition
AU2022250323A1 (en) * 2021-03-31 2023-11-09 Nihon Medi-Physics Co., Ltd. Radioactive complex of anti-egfr antibody, and radiopharmaceutical
US20240182586A1 (en) * 2021-05-11 2024-06-06 Northeastern University Site-Specific Modification of Glycoproteins Through Transglutaminase-Mediated Conjugation
WO2023190402A1 (en) * 2022-03-30 2023-10-05 日本メジフィジックス株式会社 Method for producing complex
WO2024030772A1 (en) * 2022-08-01 2024-02-08 Portland State University High relaxivity contrast agents and stereoselective preparation
WO2024059908A1 (en) * 2022-09-21 2024-03-28 The University Of Melbourne Radiolabelled compounds
WO2024107762A2 (en) * 2022-11-14 2024-05-23 Aktis Oncology, Inc. Decreased retention of miniproteins in kidney

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US20080220448A1 (en) * 2006-09-01 2008-09-11 Blincko Stuart J Antigenic protein conjugates and process for preparing same
EP2454598B1 (en) * 2009-07-15 2017-03-22 DiaTech Holdings, Inc. Drug selection for gastric cancer therapy using antibody-based arrays
US10434197B2 (en) 2010-07-23 2019-10-08 University Of Delaware Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes
WO2012075361A2 (en) * 2010-12-02 2012-06-07 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
CN103764665A (en) * 2011-06-28 2014-04-30 怀特黑德生物医学研究所 Using sortases to install click chemistry handles for protein ligation
US20150246146A1 (en) * 2012-10-25 2015-09-03 Life Technologies Corporation Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins
WO2015057066A1 (en) * 2013-10-14 2015-04-23 Synaffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
US10556024B2 (en) 2013-11-13 2020-02-11 Whitehead Institute For Biomedical Research 18F labeling of proteins using sortases
CA2949365A1 (en) * 2014-05-16 2015-11-19 Memorial Sloan Kettering Cancer Center One-step labeling of antibodies to high specific activity with actinium-225
GB201417067D0 (en) * 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
WO2016054277A1 (en) * 2014-09-30 2016-04-07 University Of Pittsburgh -Of The Commonwealth System Of Higher Education Cu(i)-catalyzed azide-alkyne cycloadditions (cuaac) ligands and methods for carrying out cu(i)-catalyzed azide- alkyne cycloaddition reactions
GB201504064D0 (en) * 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
JP2019522625A (en) * 2016-05-02 2019-08-15 ユニバーシティ オブ ピッツバーグ −オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Dimerization strategies and compounds for molecular imaging and / or radioimmunotherapy

Also Published As

Publication number Publication date
IL275242A (en) 2020-07-30
AU2018388467A1 (en) 2020-06-11
CA3085465A1 (en) 2019-06-27
EA202091420A1 (en) 2020-09-10
KR20200100094A (en) 2020-08-25
CN111491670A (en) 2020-08-04
US20210017099A1 (en) 2021-01-21
WO2019125982A1 (en) 2019-06-27
ZA202004424B (en) 2022-06-29
JP2021506842A (en) 2021-02-22
BR112020012099A2 (en) 2020-11-17
JP2023078366A (en) 2023-06-06
EP3727474A1 (en) 2020-10-28
MX2020006395A (en) 2020-12-03
PH12020550690A1 (en) 2021-04-12

Similar Documents

Publication Publication Date Title
ZA202004424B (en) Radiolabeling of polypeptides
IL262482A (en) Novel polypeptides
GB2596983B (en) Measurement of edema
ZA201802261B (en) Polypeptides
IL255767A (en) Novel polypeptides
GB201706477D0 (en) Modification of polypeptides
HK1250041A1 (en) Polypeptides
AU201614763S (en) Watchcase
GB201611530D0 (en) Novel polypeptides
IL269409A (en) Combinations of chk1- and wee1 - inhibitors
GB201700086D0 (en) Codec
ZA201704366B (en) Il-17a-binding polypeptides
HK1250040A1 (en) Polypeptides
IL265628A (en) Solid state forms of valbenazine
GB201707139D0 (en) Polypeptides
GB201619652D0 (en) Novel polypeptides
GB201602857D0 (en) Connection of rotatable parts
SG11201609739UA (en) Derivatives of dolaproine-dolaisoleuine peptides
GB201713559D0 (en) Modification of polypeptides
GB201622143D0 (en) Modification of polypeptides
GB201721386D0 (en) Chrondogy of time-wave
GB201717958D0 (en) Novel polypeptides
GB201706915D0 (en) Novel polypeptides
GB201708700D0 (en) Improvements of magflow meters
ZAA201601633S (en) Watch